Advanced Practice Providers

Olaparib is an oral drug manufactured in 150-mg and 100-mg tablets. Olaparib is taken by mouth, twice daily. It can be taken without or without food.

Patients with heavily pretreated clear cell gynecologic cancer achieved encouraging responses with single-agent pembrolizumab.

The overall survival benefit associated with pembrolizumab for patients with head and neck cancer continued to be observed at a 4-year follow-up of the KEYNOTE-048 trial.

HER2-directed antibody-drug conjugates (ADCs) play an important role in the treatment of breast and gastric cancer.

A 5-year follow-up of the COLOMBUS trial showed that encorafenib plus binimetinib continued to provide clinical benefit for patients with melanoma harboring a BRAF V600 mutation.

An analysis of patient-reported outcomes showed that patients with advanced ovarian cancer experienced fewer abdominal or gastrointestinal toxicities with mirvetuximab soravtansine than with chemotherapy.

Advanced practice providers are the future of survivorship care because of the tremendous value they offer to the practice and its patients.

Optimal treatment sequencing for patients with BRAF-mutated melanoma involves frontline immunotherapy following by BRAF/MEK inhibition, according to investigators.

At the 2022 ASCO Quality Care Symposium, an adverse event analysis showed that abemaciclib has a manageable safety profile and that dose reductions may be a key aspect of appropriate symptom management.

Elacestrant, an oral selective estrogen receptor degrader, may hold the potential to replace intramuscular fulvestrant injections for patients with endocrine receptor–positive, HER2-negative breast cancer.

Menstrual suppression can improve outcomes and quality of life in premenopausal women undergoing hematopoietic stem cell transplant.

Kristin Barber, APRN, AOCNP, FNP-BC, unpacks the FDA approval of durvalumab in combination with cisplatin and gemcitabine for patients with biliary tract cancers.

Following potential safety concerns with 3 PARP inhibitors, manufactures have voluntarily elected to withdraw the indications for patients with heavily pretreated patients with BRCA-mutated ovarian cancer.

The FDA has approved sodium thiosulfate to protect the hearing of pediatric patients who are at least 1 year old and are receiving cisplatin-based treatments.

Intense-modulated therapy was associated with less patient-reported toxicities than conventional radiotherapy and demonstrated a comparable efficacy profile.

The FDA has approved eflapegrastim to treat febrile neutropenia. The agent should be administered 24 hours following cytotoxic chemotherapy. It comes with warnings for fatal splenic rupture, acute respiratory distress syndrome, sickle cell crisis, glomerulonephritis, leukocytosis, thrombocytopenia, and myelodysplastic syndrome.

In a presentation at the 2022 Oncology Nursing Society Bridge, Stephany L. Rodriguez, RN, MS, NP, discussed the later effects associated with hematopoietic stem cell transplant and how to manage them.

The rate of event-free survival associated with pembrolizumab was significantly higher among patients with high-risk melanoma about to undergo surgery than among those who received immunotherapy following surgery.

Patients with relapsed or refractory metastatic colorectal cancer who received dose-optimized regorafenib achieved superior survival outcomes than those who received best supportive care, fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil.

Kelly Goodwin, MSN, RN, ANP-BC, discusses the significance of the recent FDA approvals of capmatinib and trastuzumab deruxtecan for patients with non–small cell lung cancer.

Adding plinabulin to prophylactic pegfilgrastim and antibiotics may help prevent nonengraftment–related febrile neutropenia.

Best management strategies for vancomycin infusion reactions may include premedication, infusion-rate adjustment, and, in some cases, alternative antibiotic therapy.

In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.

Sotorasib is often associated with a high rate of hepatotoxic events, most of which are from elevated liver enzymes. However, a lead-in dosing strategy may help address this adverse event and improve patient tolerability.

A post hoc analysis from the phase 2 DREAMM-2 trial highlighted the ocular toxicity risks that belantamab mafodotin poses for patients with multiple myeloma.

An observational study found no association between single-agent vaginal estrogen therapy or menopausal hormone therapy and increased risk of recurrence or mortality in patients with breast cancer.

Starting patients with unresectable or metastatic renal cell carcinoma on a reduced dose of VEGF tyrosine kinase inhibitor (TKI) therapy did not compromise survival outcomes.

A combination of niraparib plus ipilimumab were associated with a 6-month PFS rate of 59.6%, whereas a combination of nivolumab plus the PARP inhibitor yielded a rate of 20.6%.